Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

Exclusion Criteria

• •1. Diagnosis of small cell (neuroendocrine) histology or mucinous adenocarcinoma cervical cancer
• •2. Intent to administer a fertility-sparing treatment regimen
• •3. Undergone a previous hysterectomy
• •4. Evidence of metastatic disease per RECIST 1.1 including lymph nodes ≥15 mm (short axis) above the L1 cephalad body, in the inguinal region or outside the planned radiation field.
• •5. History of allogeneic organ transplantation
• •6. Active or prior documented autoimmune or inflammatory disorders
• •7. Uncontrolled intercurrent illness
• •8. History of another primary malignancy and active primary immunodeficiency